Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology

Joe Sasadeusz, Andrew Grigg, Peter D. Hughes, Seng Lee Lim, Michaela Lucas, Geoff McColl, Sue Anne McLachlan, Marion G. Peters, Nicholas Shackel, Monica Slavin, Vijaya Sundararajan, Alexander Thompson, Joseph Doyle, James Rickard, Peter De Cruz, Robert G. Gish, Kumar Visvanathan

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Current recommendations concerning hepatitis C virus (HBV) reactivation are limited, with nearly all guidelines focused on its occurrence in patients with hematological malignancies or some solid tumors, who are treated with immunosuppressive therapies. Few of the guidelines address reactivation in patients receiving immunosuppression with organ transplants or treatment with any of the many immunosuppressive agents in use today for the treatment of multiple different diseases, or in patients receiving the direct-acting antivirals used in the treatment of hepatitis C virus (HCV). This article covers the immunology of HBV reactivation, mechanisms of viral clearance, and recommendations for screening and prophylaxis.

Original languageEnglish
Pages (from-to)487-492
Number of pages6
JournalClinics in Liver Disease
Issue number3
Publication statusPublished - 1 Aug 2019


Dive into the research topics of 'Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology'. Together they form a unique fingerprint.

Cite this